
Sagimet Biosciences Investor Relations Material
Latest events

KOL Event
Sagimet Biosciences
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Sagimet Biosciences Inc
Access all reports
Sagimet Biosciences Inc., previously known as 3-V Biosciences, Inc., is a clinical-stage biopharmaceutical company. It focuses on developing innovative therapeutics called fatty acid synthase (FASN) inhibitors. These inhibitors target diseases caused by the overproduction of the fatty acid, palmitate, including non-alcoholic steatohepatitis (NASH), acne, and various forms of cancer. Sagimet Biosciences' expertise in fatty acid synthase allows it to pioneer treatments for these diseases by targeting dysfunctional metabolic pathways. Its lead product candidate, denifanstat, is an oral, once-daily selective FASN inhibitor, currently being evaluated in clinical trials for patients with NASH. The company was incorporated in 2006 and is headquartered in San Mateo, California, USA. Its shares are listed on the Nasdaq.
Key slides for Sagimet Biosciences Inc


Corporate Presentation
Sagimet Biosciences Inc


Corporate Presentation
Sagimet Biosciences Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
SGMT
Country
🇺🇸 United States